Abstract 2636
Background
Advances in the treatment of localized CaP have led to decreased recurrences and improved OS. The Intermediate Clinical Endpoints in CaP (ICECaP) Working Group is conducting meta-analysis of potential surrogate endpoints for localized CaP trials. We hypothesized that MFS is a surrogate for OS.
Methods
By June 2013, we systematically identified 102 eligible randomized trials (completed or ongoing) comparing treatments in localized CaP and collected individual patient data (IPD) from trialists. MFS was defined from randomization to the first evidence of distant metastatic disease (excluding pelvic lymph nodes), or death from any cause; or was censored at the date of last follow-up. OS was defined from randomization to death from any cause. We evaluated the surrogacy of MFS with OS using a 2-stage meta-analytic validation model where 2 conditions must hold to claim MFS is a surrogate for OS (Buyse et al, 2000 & 2011 - table). The secondary objective evaluated surrogacy of time to metastasis (TTM) with disease specific survival (DSS), defined analogously to MFS and OS but with non-CaP deaths censored.
Results
By May 2016, IPD from 12,712 men randomized in 19 mature trials between 1987 and 2010 were available for analysis. 90% of the men were from radiation based trials, 30% had intermediate and 57% high-risk disease (NCCN criteria) and 83% were
Conclusions
MFS can be used as a surrogate of OS and TTM as a surrogate of DSS.
Clinical trial identification
Legal entity responsible for the study
Dana Farber Cancer Institution, Boston, MA, United States
Funding
Prostate Cancer Foundation, CA, United States
Disclosure
C. Sweeney: consultant with compensation - Sanofi, BIND, Janssen, Astellas, Genentech, Bayer, AZ.
H.M. Sandler: Financial: Consulting: Janssen, Sanofi, Clovis Oncology, Ferring, Eviti Non-financial: Chairman, GU Cancer Committee, NRG Oncology.
All other authors have declared no conflicts of interest.
Resources from the same session
Risk of prostate cancer mortality in men with an initial benign needle core biopsy set: a population based analysis with up to 20 years of follow-up
Presenter: Nina Klemann
Session: Genitourinary tumours, prostate
Resources:
Abstract
PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Presentation
PROSELICA: Health-related quality of life (HRQL) and post-hoc analyses for the phase 3 study assessing cabazitaxel 20 (C20) vs 25 (C25) mg/m2 post-docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Genitourinary tumours, prostate
Resources:
Abstract
Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifer in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial
Presenter: Felix Feng
Session: Genitourinary tumours, prostate
Resources:
Abstract
Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 study
Presenter: Aaron Hansen
Session: Genitourinary tumours, prostate
Resources:
Abstract
Modelling relapse in patients with high-risk localised prostate cancer treated randomly in the GETUG 12 phase III trial reveals two populations of relapsing patients
Presenter: Cécile Vicier
Session: Genitourinary tumours, prostate
Resources:
Abstract
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
Presenter: Christopher Sweeney
Session: Genitourinary tumours, prostate
Resources:
Abstract
Invited discussant abstracts LBA29 and 719O
Presenter: Winald Gerritsen
Session: Genitourinary tumours, prostate
Resources:
Presentation
Invited discussant abstracts 725PD, 726PD, 727PD, 728PD, 729PD and 730PD
Presenter: David Olmos
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast
Invited discussant abstracts 720PD, 721PD, 722PD, 723PD and 724PD
Presenter: Matthew Sydes
Session: Genitourinary tumours, prostate
Resources:
Presentation
Webcast